3518 related articles for article (PubMed ID: 6676498)
1. [Immunological analysis of melanoma specific antigen. (I). In-vitro induction of melanoma-antigen specific killer T lymphocytes in primary immune response].
Wakabayashi S; Taniguchi M; Tomioka H; Okamoto S
Nihon Hifuka Gakkai Zasshi; 1983 Dec; 93(14):1469-76. PubMed ID: 6676498
[No Abstract] [Full Text] [Related]
2. [Immunological analysis of melanoma-specific antigen].
Wakabayashi S; Okamoto S
Nihon Hifuka Gakkai Zasshi; 1985 Oct; 95(11):1145-51. PubMed ID: 3879298
[No Abstract] [Full Text] [Related]
3. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
4. Identification of a structure on human melanoma cells recognized by CTL exhibiting anomalous killer cell function.
Werkmeister JA; Triglia T; Andrews P; Burns GF
J Immunol; 1985 Jul; 135(1):689-95. PubMed ID: 3873498
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.
Ribas A; Amarnani SN; Buga GM; Butterfield LH; Dissette VB; McBride WH; Glaspy JA; Ignarro LJ; Economou JS
Cancer Gene Ther; 2002 Nov; 9(11):875-83. PubMed ID: 12386826
[TBL] [Abstract][Full Text] [Related]
7. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
8. Melanoma and immunity.
Rheins LA; Nordlund JJ
Immunol Ser; 1989; 46():769-87. PubMed ID: 2484957
[No Abstract] [Full Text] [Related]
9. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
Kahn M; Sugawara H; McGowan P; Okuno K; Nagoya S; Hellström KE; Hellström I; Greenberg P
J Immunol; 1991 May; 146(9):3235-41. PubMed ID: 1707934
[TBL] [Abstract][Full Text] [Related]
10. [Immunological analysis of melanoma specific antigen. II. Inhibition of killer T cell activity by anti-melanoma antibody and anti-H-2b antibody].
Wakabayashi S; Taniguchi M; Tomioka H; Okamoto S
Nihon Hifuka Gakkai Zasshi; 1984 Feb; 94(2):143-9. PubMed ID: 6610781
[No Abstract] [Full Text] [Related]
11. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
[TBL] [Abstract][Full Text] [Related]
12. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
13. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight.
Hussein MR
Br J Dermatol; 2005 Jul; 153(1):18-21. PubMed ID: 16029321
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
Baumgaertner P; Rufer N; Devevre E; Derre L; Rimoldi D; Geldhof C; Voelter V; Liénard D; Romero P; Speiser DE
Cancer Res; 2006 Feb; 66(4):1912-6. PubMed ID: 16488988
[TBL] [Abstract][Full Text] [Related]
16. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
17. The NK function elucidated with respect to effector cells, target cells and other immunological in vitro tests.
Kristensen E
Tokai J Exp Clin Med; 1983 Dec; 8(5-6):449-53. PubMed ID: 6681340
[TBL] [Abstract][Full Text] [Related]
18. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T cell response against a non-tumor antigen is unaffected in melanoma-bearing mice.
de Souza AP; de Jesus Borges T; Pillat MM; Bonorino C
Cancer Immunol Immunother; 2011 Jan; 60(1):145-51. PubMed ID: 20963412
[TBL] [Abstract][Full Text] [Related]
20. Immunology. Stress, NK receptors, and immune surveillance.
Pardoll DM
Science; 2001 Oct; 294(5542):534-6. PubMed ID: 11567108
[No Abstract] [Full Text] [Related]
[Next] [New Search]
